Can Alto Neuroscience’s ALTO-101 finally move the needle on cognitive impairment in schizophrenia?
Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in CIAS. Discover what the upcoming data could mean for precision psychiatry.
Pharma & Biotech
Pharma & Biotech
Is Novartis Pharma AG positioned to convert accelerated approval for Vanrafia in 2026?
Novartis reports Phase III ALIGN data for Vanrafia in IgA nephropathy. Discover what this means for full approval in 2026.
Medical Devices & Diagnostics
Medtronic secures FDA clearance for Stealth AXiS surgical system in spine robotics
Medtronic wins FDA clearance for Stealth AXiS in spine robotics. Explore what this integrated platform means for workflow, data, and adoption.
Pharma & Biotech
Can online therapy finally close New Mexico’s mental health gap? SkyMD bets big on statewide virtual care
SkyMD launches statewide online therapy in New Mexico. Find out what this expansion means for access, regulation, and teletherapy adoption.
Pharma & Biotech
What the FDA decision on PTC Therapeutics’ Translarna reveals about Duchenne muscular dystrophy drug approvals
PTC Therapeutics has withdrawn its U.S. filing for Translarna. Find out what this means for Duchenne drug development and FDA expectations.
Pharma & Biotech
Why Hurricane Ventures’ investment in BioReact highlights the next phase of digital bioprocessing
UTulsa-backed BioReact targets bioprocess inefficiencies with AI analytics. Discover what this investment could change for biopharma development and manufacturing.
Pharma & Biotech
Can Innovent’s IBI354 replace chemotherapy in first-line HER2-positive metastatic breast cancer
Innovent Biologics advances IBI354 into phase 3 first-line HER2-positive breast cancer. Find out what this means for ADC competition and clinical practice.
Pharma & Biotech
What CARsgen Therapeutics’ RMB370m manufacturing plan reveals about CAR-T execution risk
CARsgen Therapeutics is expanding CAR-T manufacturing in Shanghai as solid tumor programs near approval. Find out why this matters for scale and adoption.
Medical Devices & Diagnostics
Does WHOOP’s biomarker integration move wearables closer to regulated healthcare?
WHOOP launches Advanced Labs in the UAE with Unilabs, integrating 65 biomarkers into its wearable platform. Explore what this shift means.
Pharma & Biotech
How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine
Galderma launches a two-year Sculptra initiative tracking real-world outcomes. Discover what this means for regenerative aesthetics and durability claims.